Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Poly[N-(2-hydroxypropyl)methacrylamide]-Modified Magnetic γ-F2 O3 Nanoparticles Conjugated with Doxorubicin for Glioblastoma Treatment

Z. Plichta, D. Horák, D. Mareková, K. Turnovcová, R. Kaiser, P. Jendelová

. 2020 ; 15 (1) : 96-104. [pub] 20191112

Language English Country Germany

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21012926

With the aim to develop a new anticancer agent, we prepared poly[N-(2-hydroxypropyl)methacrylamide-co-methyl 2-methacrylamidoacetate] [P(HP-MMAA)], which was reacted with hydrazine to poly[N-(2-hydroxypropyl)methacrylamide-co-N-(2-hydrazinyl-2-oxoethyl)methacrylamide] [P(HP-MAH)] to conjugate doxorubicin (Dox) via hydrazone bond. The resulting P(HP-MAH)-Dox conjugate was used as a coating of magnetic γ-Fe2 O3 nanoparticles obtained by the coprecipitation method. In vitro toxicity of various concentrations of Dox, P(HP-MAH)-Dox, and γ-Fe2 O3 @P(HP-MAH)-Dox nanoparticles was determined on somatic healthy cells (human bone marrow stromal cells hMSC), human glioblastoma line (GaMG), and primary human glioblastoma (GBM) cells isolated from GBM patients both at a short and prolonged exposition time (up to 7 days). Due to hydrolysis of the hydrazone bond in acid milieu of tumor cells and Dox release, the γ-Fe2 O3 @P(HP-MAH)-Dox nanoparticles significantly decreased the GaMG and GBM cell growth compared to free Dox and P(HP-MAH)-Dox in low concentration (10 nM), whereas in hMSCs it remained without effect. γ-F2 O3 @PHP nanoparticles alone did not affect the viability of any of the tested cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012926
003      
CZ-PrNML
005      
20210716111903.0
007      
ta
008      
210420s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cmdc.201900564 $2 doi
035    __
$a (PubMed)31670889
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Plichta, Zdeněk $u Department of Polymer Particles, Institute of Macromolecular Chemistry CAS, Heyrovského nám. 2, 162 06, Prague 6, Czech Republic
245    10
$a Poly[N-(2-hydroxypropyl)methacrylamide]-Modified Magnetic γ-F2 O3 Nanoparticles Conjugated with Doxorubicin for Glioblastoma Treatment / $c Z. Plichta, D. Horák, D. Mareková, K. Turnovcová, R. Kaiser, P. Jendelová
520    9_
$a With the aim to develop a new anticancer agent, we prepared poly[N-(2-hydroxypropyl)methacrylamide-co-methyl 2-methacrylamidoacetate] [P(HP-MMAA)], which was reacted with hydrazine to poly[N-(2-hydroxypropyl)methacrylamide-co-N-(2-hydrazinyl-2-oxoethyl)methacrylamide] [P(HP-MAH)] to conjugate doxorubicin (Dox) via hydrazone bond. The resulting P(HP-MAH)-Dox conjugate was used as a coating of magnetic γ-Fe2 O3 nanoparticles obtained by the coprecipitation method. In vitro toxicity of various concentrations of Dox, P(HP-MAH)-Dox, and γ-Fe2 O3 @P(HP-MAH)-Dox nanoparticles was determined on somatic healthy cells (human bone marrow stromal cells hMSC), human glioblastoma line (GaMG), and primary human glioblastoma (GBM) cells isolated from GBM patients both at a short and prolonged exposition time (up to 7 days). Due to hydrolysis of the hydrazone bond in acid milieu of tumor cells and Dox release, the γ-Fe2 O3 @P(HP-MAH)-Dox nanoparticles significantly decreased the GaMG and GBM cell growth compared to free Dox and P(HP-MAH)-Dox in low concentration (10 nM), whereas in hMSCs it remained without effect. γ-F2 O3 @PHP nanoparticles alone did not affect the viability of any of the tested cells.
650    _2
$a akrylamidy $x chemie $7 D000178
650    _2
$a protinádorové látky $x chemie $x metabolismus $x farmakologie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $7 D049109
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a doxorubicin $x chemie $x metabolismus $x farmakologie $7 D004317
650    _2
$a nosiče léků $x chemie $7 D004337
650    _2
$a uvolňování léčiv $7 D065546
650    _2
$a železité sloučeniny $x chemie $7 D005290
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a glioblastom $x patologie $7 D005909
650    _2
$a lidé $7 D006801
650    _2
$a magnetické nanočástice $x chemie $7 D058185
650    _2
$a polymery $x chemie $7 D011108
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Horák, Daniel $u Department of Polymer Particles, Institute of Macromolecular Chemistry CAS, Heyrovského nám. 2, 162 06, Prague 6, Czech Republic
700    1_
$a Mareková, Dana $u Department of Neuroregeneration, Institute of Experimental Medicine CAS, Vídeňská 1083, 142 20, Prague 4, Czech Republic ; 2nd Faculty of Medicine, Charles University, V úvalu 84, 150 06, Prague 5, Czech Republic
700    1_
$a Turnovcová, Karolína $u Department of Neuroregeneration, Institute of Experimental Medicine CAS, Vídeňská 1083, 142 20, Prague 4, Czech Republic
700    1_
$a Kaiser, Radek $u Department of Neurosurgery and Neurooncology, First Faculty of Medicine and Military University Hospital, U Vojenské nemocnice 1200, 169 02, Prague 6, Czech Republic
700    1_
$a Jendelová, Pavla $u Department of Neuroregeneration, Institute of Experimental Medicine CAS, Vídeňská 1083, 142 20, Prague 4, Czech Republic ; 2nd Faculty of Medicine, Charles University, V úvalu 84, 150 06, Prague 5, Czech Republic
773    0_
$w MED00173270 $t ChemMedChem $x 1860-7187 $g Roč. 15, č. 1 (2020), s. 96-104
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31670889 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210716111904 $b ABA008
999    __
$a ok $b bmc $g 1651159 $s 1133305
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 15 $c 1 $d 96-104 $e 20191112 $i 1860-7187 $m ChemMedChem $n ChemMedChem $x MED00173270
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options